Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients ...

Chiesi is working with the BBC to show off its climate-conscious credentials, partnering with the British broadcaster on a web series episode about redesigning inhalers to reduce their environmental ...

Chiesi Group announces that it has successfully completed a Phase I trial of its inhaled PDE4 (phosphodiesterase 4) inhibitor, denoted CHF 6001, a new chemical entity developed for the treatment of ...

WOODBURY, Minn.--(BUSINESS WIRE)--Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart (a division of the Heitkamp ...

Chiesi Group proudly shares its contribution to the thought-provoking series "The Climate and Us", presented by the Global Climate and Health Alliance and produced for them by BBC StoryWorks. The ...

In 2023, Chiesi group's revenue exceeded 3 billion euros ($3.24 billion), representing a 10 percent increase from 2022, with ...

Forbes contributors publish independent expert analyses and insights. I write about businesses creating a more sustainable economic system. With a two-pronged focus on research and sustainability, a ...

Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, ...